<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The hallmark of Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) is a constitutively activated c-myc gene that drives <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell growth </plain></SENT>
<SENT sid="1" pm="."><plain>A majority of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>-derived cell lines also carry mutant p53 </plain></SENT>
<SENT sid="2" pm="."><plain>In addition, the p16INK4a promoter is hypermethylated in most <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> biopsies and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell lines, leading to silencing of this gene </plain></SENT>
<SENT sid="3" pm="."><plain>Activation of c-myc and/or cell cycle dysregulation can induce ARF expression and p53-dependent <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="4" pm="."><plain>We therefore investigated the p14ARF-MDM2-p53 pathway in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell lines </plain></SENT>
<SENT sid="5" pm="."><plain>p14ARF was expressed and localized to nucleoli in <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> carrying mutant p53 </plain></SENT>
<SENT sid="6" pm="."><plain>Three out of seven <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> carrying wt p53 had a homozygous deletion of the CDKN2A locus that encodes both p14ARF and p16INK4a </plain></SENT>
<SENT sid="7" pm="."><plain>Three <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> carrying <z:mp ids='MP_0002169'>wild type</z:mp> p53 retained the CDKN2A locus and overexpressed MDM2 </plain></SENT>
<SENT sid="8" pm="."><plain>DNA sequencing revealed a point mutation in CDKN2A exon 2 in one of these <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>, Seraphine </plain></SENT>
<SENT sid="9" pm="."><plain>However, this point mutation did not affect p14ARF's nucleolar localization or ability to induce p53 </plain></SENT>
<SENT sid="10" pm="."><plain>The Bmi-1 protein that negatively regulates the p14ARF promoter and co-operates with c-myc in <z:mp ids='MP_0002006'>tumorigenesis</z:mp> was expressed at low to moderate levels in <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> analysed </plain></SENT>
<SENT sid="11" pm="."><plain>Our results indicate that inactivation of the ARF-MDM2-p53 pathway is an essential step during the development of Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, presumably as a mechanism to escape c-myc induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
</text></document>